African animal trypanosomiasis (AAT) is a disease of vertebrate animals caused by a blood‑dwelling protozoan parasite which is spread by biting tsetse flies.
AAT is widely known in Africa as nagana and is a major constraint for livestock producers in sub-Saharan Africa. Each year, AAT is estimated to kill 3 million cattle. The direct economic cost arising from mortality and morbidity caused by AAT is estimated to be USD650 million annually. However, by including wider social and economic effects, the overall cost could be as high as USD4.75 billion per annum. (Budd, 1999)
One of GALVmed’s partners, the University of Glasgow, has produced a short video addressing the challenges of AAT in Tanzania and explains why a more effective drug is needed.
The de-risking and ultimate development of a new drug and its commercialisation would translate to a better and effective control of AAT. This would benefit small-scale livestock producers’ interests and reduce the risk of African human trypanosomiasis in affected areas.
For more information about GALVmed’s African Animal Trypanosomosis programme, please visit our Product Development page.